Agenus (NASDAQ:AGEN) Share Price Passes Above Two Hundred Day Moving Average – What’s Next?

Agenus Inc. (NASDAQ:AGEN)’s stock price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.43 and traded as high as $3.43. Agenus shares last traded at $3.41, with a volume of 659,577 shares trading hands.

Analyst Upgrades and Downgrades

Several brokerages recently commented on AGEN. Weiss Ratings restated a “sell (d)” rating on shares of Agenus in a research report on Tuesday, June 16th. Wall Street Zen raised Agenus from a “hold” rating to a “buy” rating in a research report on Monday, April 6th. Finally, Zacks Research downgraded Agenus from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $23.00.

Agenus Stock Performance

The business’s 50-day simple moving average is $3.37 and its 200-day simple moving average is $3.43. The company has a market cap of $145.32 million, a PE ratio of 2.19 and a beta of 1.55.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Monday, May 11th. The biotechnology company reported $1.02 EPS for the quarter, missing the consensus estimate of $2.10 by ($1.08). The company had revenue of $33.74 million for the quarter, compared to analysts’ expectations of $129.50 million. Agenus had a net margin of 50.49% and a negative return on equity of 31.66%. On average, research analysts predict that Agenus Inc. will post 0.02 earnings per share for the current fiscal year.

Institutional Trading of Agenus

Several large investors have recently added to or reduced their stakes in AGEN. Bank of America Corp DE boosted its holdings in Agenus by 796.7% in the first quarter. Bank of America Corp DE now owns 118,782 shares of the biotechnology company’s stock worth $397,000 after purchasing an additional 105,536 shares in the last quarter. Redwood Family Wealth LLC bought a new position in Agenus during the fourth quarter valued at about $44,000. Ovata Capital Management Ltd acquired a new stake in shares of Agenus in the fourth quarter worth about $97,000. Virtu Financial LLC acquired a new stake in shares of Agenus in the fourth quarter worth about $108,000. Finally, EP Wealth Advisors LLC bought a new stake in shares of Agenus during the 4th quarter worth about $31,000. 61.46% of the stock is owned by institutional investors.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.